COH — Cochlear Share Price
Last trade - 00:00- AU$16.13bn
- AU$15.83bn
- AU$1.65bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 46.36 | ||
| PEG Ratio (f) | 3.91 | ||
| EPS Growth (f) | 13.45% | ||
| Dividend Yield (f) | 1.52% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.4 | ||
| Price to Tang. Book | 12.34 | ||
| Price to Free Cashflow | 62.31 | ||
| Price to Sales | 9.42 | ||
| EV to EBITDA | 36.21 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 17.54% | ||
| Return on Equity | 15.18% | ||
| Operating Margin | 20.51% | ||
Financial Summary
| Year End 30th Jun | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 1,363.7 | 1,426.7 | 1,320.6 | 1,497.6 | 1,648.3 | 1,856.39 | 2,067.69 | 5.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +8.52 | +9.09 | +16.86 | -5.85 | -13.27 | +3.34 | +14.36 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cochlear Limited is an Australia-based company, which provides implantable hearing solutions and sound processors. The Company designs and offers products and accessories for adults or children. The Company operates through three segments: Cochlear implants, Services and Acoustics. The Company’s Cochlear implants segment offers Cochlear implant systems, including Cochlear Nucleus Profile Plus with Slim Modiolar Electrode (CI632). Its Services segment offers sound processor upgrades, accessories and other, including Cochlear Nucleus 7 Sound Processor and Cochlear Nucleus Kanso 2 Sound Processor. Its Acoustics segment offers Bone Conduction systems and Sound processor upgrades, including Cochlear Osia 2 System and Cochlear Baha 6 Max Sound Processor. Its products and accessories include Cochlear Nucleus System, Cochlear Baha System and Cochlear Baha Start. The Company operates in America; Europe, the Middle East and Africa (EMEA), and Asia Pacific.
Directors
- Alison Deans NEC (53)
- Diggory Howitt PRE (54)
- Stuart Sayers CFO
- Anthony Bishop CEX
- Richard Brook CEX
- Tony Manna CEX
- Dean Phizacklea SVP
- Greg Bodkin SVP
- Jennifer Hornery SVP
- Brian Kaplan SVP
- Jan Janssen CTO
- David Hackshall CIO
- Ray Jarman SEC
- Michael Daniell NED (65)
- Andrew Denver NED
- Yasmin Allen NID (57)
- Glen Boreham NID (57)
- Michael Del Prado NID
- Christine McLoughlin NID
- Bruce Robinson NID (65)
- Last Annual
- June 30th, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- June 8th, 1983
- Public Since
- December 4th, 1995
- No. of Shareholders
- 46,308
- No. of Employees
- 4,500
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 65,781,412
- Address
- 1 University Avenue, SYDNEY, 2109
- Web
- https://www.cochlear.com/sg/en/home
- Phone
- +61 294286555
- Contact
- Jennifer Stevenson
- Auditors
- KPMG
Latest News for COH
Upcoming Events for COH
Full Year 2023 Cochlear Ltd Earnings Release
Cochlear Ltd Annual Shareholders Meeting
Similar to COH
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Orthopaedics
Australian Stock Exchange - SEATS
Analytica
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
FAQ
As of Today at 07:05 UTC, shares in Cochlear are trading at AU$245.15. This share price information is delayed by 15 minutes.
Shares in Cochlear last closed at AU$245.15 and the price had moved by +12.2% over the past 365 days. In terms of relative price strength the Cochlear share price has outperformed the ASX All Ordinaries Index by +15.07% over the past year.
The overall consensus recommendation for Cochlear is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Cochlear dividend yield is 0.79% based on the trailing twelve month period.
Last year, Cochlear paid a total dividend of AU$1.94, and it currently has a trailing dividend yield of 0.79%. We do not have any data on when Cochlear is to next pay dividends.
We do not have data on when Cochlear is to next pay dividends. The historic dividend yield on Cochlear shares is currently 0.79%.
To buy shares in Cochlear you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$245.15, shares in Cochlear had a market capitalisation of AU$16.13bn.
Here are the trading details for Cochlear:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: COH
Based on an overall assessment of its quality, value and momentum Cochlear is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cochlear is AU$226.40. That is 7.65% below the last closing price of AU$245.15.
Analysts covering Cochlear currently have a consensus Earnings Per Share (EPS) forecast of AU$4.67 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cochlear. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +16.82%.
As of the last closing price of AU$245.15, shares in Cochlear were trading +12.49% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cochlear PE ratio based on its reported earnings over the past 12 months is 46.36. The shares last closed at AU$245.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cochlear's management team is headed by:
- Alison Deans - NEC
- Diggory Howitt - PRE
- Stuart Sayers - CFO
- Anthony Bishop - CEX
- Richard Brook - CEX
- Tony Manna - CEX
- Dean Phizacklea - SVP
- Greg Bodkin - SVP
- Jennifer Hornery - SVP
- Brian Kaplan - SVP
- Jan Janssen - CTO
- David Hackshall - CIO
- Ray Jarman - SEC
- Michael Daniell - NED
- Andrew Denver - NED
- Yasmin Allen - NID
- Glen Boreham - NID
- Michael Del Prado - NID
- Christine McLoughlin - NID
- Bruce Robinson - NID